title: Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.
abstract: OBJECTIVE
  Androgen-deprivation therapy (ADT) for prostate cancer is associated with bone loss and osteoporotic fractures. Our objective was to examine changes in bone density and turnover with sustained, discontinued, or delayed oral bisphosphonate therapy in men receiving ADT.
  
  
  METHODS
  A total of 112 men with nonmetastatic prostate cancer receiving ADT were randomly assigned to alendronate 70 mg once weekly or placebo in a double-blind, partial-crossover trial with a second random assignment at year 2 for those who initially received active therapy. Outcomes included bone mineral density and bone turnover markers.
  
  
  RESULTS
  Men initially randomly assigned to alendronate and randomly reassigned at year 2 to continue had additional bone density gains at the spine (mean, 2.3% +/- 0.7) and hip (mean, 1.3% +/- 0.5%; both P < .01); those randomly assigned to placebo in year 2 maintained density at the spine and hip but lost (mean, -1.9% +/- 0.6%; P < .01) at the forearm. Patients randomly assigned to begin alendronate in year 2 experienced improvements in bone mass at the spine and hip, but experienced less of an increase compared with those who initiated alendronate at baseline. Men receiving alendronate for 2 years experienced a mean 6.7% (+/- 1.2%) increase at the spine and a 3.2% (+/- 1.5%) at the hip (both P < .05). Bone turnover remained suppressed.
  
  
  CONCLUSIONS
  Among men with nonmetastatic prostate cancer receiving ADT, once-weekly alendronate improves bone density and decreases turnover. A second year of alendronate provides additional skeletal benefit, whereas discontinuation results in bone loss and increased bone turnover. Delay in bisphosphonate therapy appears detrimental to bone health.
authors.affiliation: Divisions of Geriatric Medicine and Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, PA 15213-3221, USA. greenspans@dom.pitt.edu
authors.forename: Susan L
authors.initials: SL
authors.lastname: Greenspan
authors.forename: Joel B
authors.initials: JB
authors.lastname: Nelson
authors.forename: Donald L
authors.initials: DL
authors.lastname: Trump
authors.forename: Julie M
authors.initials: JM
authors.lastname: Wagner
authors.forename: Megan E
authors.initials: ME
authors.lastname: Miller
authors.forename: Subashan
authors.initials: S
authors.lastname: Perera
authors.forename: Neil M
authors.initials: NM
authors.lastname: Resnick
mesh_terms: D000284:Administration, Oral; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D050723:Fractures, Bone / Q000517:prevention & control*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006727:Hormone Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D018570:Risk Assessment
chemical_list: D050071:Bone Density Conservation Agents; D006727:Hormone Antagonists; D007987:Gonadotropin-Releasing Hormone; D019386:Alendronate
references.citation: J Urol. 2001 Nov;166(5):1724-8
references.pmid: 11586210
references.citation: J Urol. 2002 Jun;167(6):2361-7; discussion 2367
references.pmid: 11992038
references.citation: Ann Intern Med. 2002 Dec 3;137(11):875-83
references.pmid: 12458987
references.citation: Cancer. 2003 Feb 1;97(3 Suppl):789-95
references.pmid: 12548577
references.citation: J Urol. 2003 Jun;169(6):2008-12
references.pmid: 12771706
references.citation: J Natl Cancer Inst. 2003 Jul 2;95(13):981-9
references.pmid: 12837834
references.citation: Eur Urol. 2004 Jan;45(1):26-34
references.pmid: 14667511
references.citation: Cancer. 2004 Mar 1;100(5):892-9
references.pmid: 14983482
references.citation: N Engl J Med. 2004 Mar 18;350(12):1189-99
references.pmid: 15028823
references.citation: Urol Clin North Am. 2004 May;31(2):331-52
references.pmid: 15123412
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2141-9
references.pmid: 15169800
references.citation: Cancer. 2004 Aug 1;101(3):541-9
references.pmid: 15274067
references.citation: Am J Clin Nutr. 1987 Oct;46(4):685-7
references.pmid: 3661483
references.citation: BJU Int. 2000 Sep;86(4):449-52
references.pmid: 10971270
references.citation: J Clin Endocrinol Metab. 2000 Sep;85(9):3109-15
references.pmid: 10999794
references.citation: Urology. 2001 Jan;57(1):127-32
references.pmid: 11164157
references.citation: J Clin Endocrinol Metab. 2001 Jun;86(6):2787-91
references.pmid: 11397888
references.citation: N Engl J Med. 2001 Sep 27;345(13):948-55
references.pmid: 11575286
references.citation: J Bone Miner Res. 1994 Aug;9(8):1137-41
references.pmid: 7976495
references.citation: Osteoporos Int. 1994 Nov;4(6):368-81
references.pmid: 7696835
references.citation: J Urol. 1997 Feb;157(2):439-44
references.pmid: 8996327
references.citation: Cancer. 1997 Feb 1;79(3):545-50
references.pmid: 9028366
references.citation: J Bone Miner Res. 1998 Dec;13(12):1915-23
references.pmid: 9844110
references.citation: Urology. 1999 Oct;54(4):607-11
references.pmid: 10510915
references.citation: Urology. 2004 Dec;64(6):1171-6
references.pmid: 15596192
references.citation: N Engl J Med. 2005 Jan 13;352(2):154-64
references.pmid: 15647578
references.citation: J Clin Endocrinol Metab. 2005 Dec;90(12):6410-7
references.pmid: 16189261
references.citation: J Clin Densitom. 2006 Jan-Mar;9(1):4-14
references.pmid: 16731426
references.citation: J Urol. 2007 Jan;177(1):17-24
references.pmid: 17161994
references.citation: J Clin Oncol. 2007 Mar 20;25(9):1038-42
references.pmid: 17369566
references.citation: Ann Intern Med. 2007 Mar 20;146(6):416-24
references.pmid: 17371886
references.citation: J Clin Endocrinol Metab. 2008 Jan;93(1):2-7
references.pmid: 18178905